drugset / Trial / NCT02354417
A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, safety study of a single ProHema-CB product administered following myeloablative conditioning regimen in pediatric subjects with hematologic malignancies.
Timeline
- Start
- 2014-12
- Primary completion
- 2016-12
- Completion
- 2017-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ProHema-CB | Cell therapy | 50 ml | — |
| Subject | ProHema-CB | Cell therapy | 150 ml | — |